Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Decision on EU marketing authorisation expected for momelotinib by early 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Subscribe To Our Newsletter & Stay Updated
